Because the absolute IgE level is often increased in patients with CRS with nasal polyps, treatment of this disease with the anti-IgE antibody omalizumab was assessed in an RCT by Pinto and co-workers in 2010 [162]. The gene discussed is IGHE; the disease is nasal cavity polyp.